Abstract:The heart is electrically and mechanically controlled as a syncytium by the autonomic nervous system. The cardiac nervous system comprises the sympathetic, parasympathetic, and sensory nervous systems that together regulate heart function on demand. Sympathetic electric activation was initially considered the main regulator of cardiac function; however, modern molecular biotechnological approaches have provided a new dimension to our understanding of the mechanisms controlling the cardiac nervous system. The heart is extensively innervated, although the innervation density is not uniform within the heart, being high in the subepicardium and the special conduction system. We and others showed previously that the balance between neural chemoattractants and chemorepellents determine cardiac nervous development, with both factors expressed in heart. Nerve growth factor is a potent chemoattractant synthesized by cardiomyocytes, whereas Sema3a is a neural chemorepellent expressed specifically in the subendocardium. Disruption of this wellorganized molecular balance and innervation density can induce sudden cardiac death due to lethal arrhythmias. In diseased hearts, various causes and mechanisms underlie cardiac sympathetic abnormalities, although their detailed pathology and significance remain contentious. We reported that cardiac sympathetic rejuvenation occurs in cardiac hypertrophy and, moreover, interleukin-6 cytokines secreted from the failing myocardium induce cholinergic transdifferentiation of the cardiac sympathetic system via a gp130 signaling pathway, affecting cardiac performance and prognosis. In this review, we summarize the molecular mechanisms involved in sympathetic development, maturation, and transdifferentiation, and propose their investigation as new therapeutic targets for heart disease. (Circ Res. 2012;110:325-336.) Key Words: cardiac sympathetic nervous system Ⅲ cardiac innervation patterning Ⅲ nerve growth factor Ⅲ cardiac rejuvenation Ⅲ cholinergic transdifferentiation Ⅲ IL-6 cytokines H eart tissue is extensively innervated via the autonomic nervous system, which comprises sympathetic and parasympathetic nerves. The cardiac sympathetic nervous system (SNS) uses norepinephrine (NE) as a neurotransmitter and increases the heart rate (chronotropic) and conduction velocity (dromotropic), as well as myocardial contraction (inotropic) and relaxation (lusitrophic). Sympathetic innervation density, which is highest in the subepicardium and central conduction system, is stringently regulated in the heart. 1 Regional differences in sympathetic innervation correspond to different areas of influence over cardiac function that cooperate to effectively control cardiac performance. Despite the clinical importance of cardiac innervation, little is known about the developmental and regulatory mechanisms underlying sympathetic innervation patterning.Cardiac innervation density is altered in pathological hearts, such as after myocardial infarction (MI), 2 in which the cardiac nerves undergo Walleria...